Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0100 • ACR Convergence 2023
The Clinical Relevance of Different Antiphospholipid Antibody Profiles in Pediatric Rheumatology Patients
Jheel Pandya, Karen Onel and Doruk Erkan, Hospital for Special Surgery, New York, NY
Background/Purpose: The clinical relevance of different antiphospholipid antibody (aPL) profiles, including low level anticardiolipin (aCL) and anti β2-glycoprotein-I (aβ2GPI) antibodies, is ill-defined in the pediatric…
Abstract Number: 0116 • ACR Convergence 2023
Integrated Metabolomic and Proteomic Analyses Stratified Patients with Antiphospholipid Syndrome According to Their Atherothrombotic Risk
Chary Lopez-Pedrera¹, Beatriz Vellón², Mª Angeles Aguirre³, Ismael Sanchez-Pareja², Laura Muñoz-Barrera², Tomás Cerdó², Pedro Segui², Christian Merlo-Ruiz², Desiree Ruiz-Vilchez², Maria del Carmen Abalos-Aguilera⁴, Nuria Barbarroja⁵, Alejandro Escudero Contreras⁶, Rafaela Ortega-Castro² and Carlos Perez-Sanchez⁷, ¹IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁴Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁵University of Cordoba, Córdoba, Spain, ⁶Reina Sofia University Hospital, Córdoba, Spain, ⁷IMIBIC, Córdoba, Spain
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by a hypercoagulable state, leading to arterial, venous, or microvascular thrombosis and accelerated atherosclerosis. Timely diagnosis…
Abstract Number: 0101 • ACR Convergence 2023
Non-Criteria Antiphospholipid Antibodies and Calprotectin as Potential Biomarkers in Pediatric Antiphospholipid Syndrome
Elizabeth Sloan¹, Katarina Kmetova², NaveenKumar K. Somanathapura², Lyndsay Kluge², Emily Chong², Claire Hoy², Srilakshmi Yalavarthi², Jacqueline Madison², Cyrus Sarosh², Lynnette Walters³, Jeanine Baisch⁴, Jessica Turnier², Virginia Pascual⁴, Tracey Wright¹, Jason Knight², Ayesha Zia¹ and Yu Zuo², ¹UT Southwestern, Dallas, TX, ²University of Michigan, Ann Arbor, MI, ³Scottish Rite Hospital for Children, Dallas, TX, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: While classification criteria for pediatric APS are not yet available, recent research suggests pediatric APS patients are unique, and many present with extra-criteria manifestations…
Abstract Number: 0579 • ACR Convergence 2023
Sub-types of Ischemic Stroke in Systemic Lupus Erythematosus,-associations with STAT4 and HLA-DRB1 Risk Genotypes
Liisa Hopia¹, Anna Laveskog², Dag Leonard³, Andreas Jonsen⁴, Johanna.T Gustafsson², Iva Gunnarsson⁵, Agneta Zickert⁶, Gunnel Nordmark⁷, Anders Bengtsson⁴, Leonid Padyukov⁸, Johanna Sandling³, Ann-Christine Syvänen⁹, Lars Rönnblom³, Magnus Andersson¹ and Elisabet Svenungsson⁶, ¹Department of Clinical Neuroscience, Unit of Neurology, Karolinska Institutet och Karolinska Universitetssjukhuset, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ⁵Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁷Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ⁸Karolinska Institutet, Solna, Sweden, ⁹Department of Medical Sciences, Molecular Medicine, Uppsala University, Uppsala, Sweden
Background/Purpose: Ischemic stroke is 2-3 times more common in patients with SLE as compared to the general population, and genetic susceptibility in the STAT4 and…
Abstract Number: 0102 • ACR Convergence 2023
The Subtype and Prognosis of Acute Myocardial Infarction in Antiphospholipid Syndrome Patients
Jeffrey Curtis¹, Kelly Gavigan², W. Benjamin Nowell³, David Curtis⁴, Danielle Ali⁵, Xiaoyu Liu⁶, Katherine Makaroff⁶, Christopher Almario⁶, Carine Khalil⁶, So Yung Choi⁷ and Brennan Spiegel⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, Nyack, NY, ⁴Global Healthy Living Foundation, San Francisco, CA, ⁵Global Healthy Living Foundation, Upper Nayack, NY, ⁶Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Los Angeles, CA, ⁷Biostatistics and Bioinformatics Research Center, Cedars-Sinai Cancer, Los Angeles, CA
Background/Purpose: Acute myocardial infarction (AMI) can be divided into coronary artery disease (MICAD) or nonobstructive coronary arteries (MINOCA) according to the severity of artery stenosis…
Abstract Number: 0738 • ACR Convergence 2023
A Genome-wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome
Desire Casares¹, Manuel Martínez-Bueno², Maria Orietta Borghi³, Guillermo Pons-Estel⁴, PRECISESADS Clinical Consortium², Yu Zuo⁵, Gerard Espinosa⁶, Alexandra Zhernakova⁷, Cisca Wijmenga⁷, Timothy Radstake⁸, Lucas van den Hoogen⁹, Guillermo Reales¹⁰, Chris Wallace¹⁰, Joel Guthridge¹¹, Judith James¹¹, Ricard Cervera¹², Pierluigi Meroni¹³, Javier Martin¹⁴, Jason Knight⁵, Marta Alarcon-Riquelme¹⁵ and Amr Sawalha¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Centre for Genomics and Oncological Research, Granada, Spain, ³University of Milan, Milan, Italy, ⁴CREAR, Rosario, Argentina, ⁵University of Michigan, Ann Arbor, MI, ⁶Hospital Clinic, Barcelona, Spain, ⁷University of Groningen, Groningen, Netherlands, ⁸University Medical Center Utrecht, Carlisle, IL, ⁹Radboudumc and Sint Maartenskliniek, Nijmegen, Netherlands, ¹⁰University of Cambridge, Cambridge, United Kingdom, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Hospital Clínic de Barcelona, Barcelona, Spain, ¹³IRCCS Istituto Auxologico Italiano, Cusano Milanino, Milan, Italy, ¹⁴Instituto de Parasitologia y Biomedicina Lopez-Neyra - CSIC, Granada, Spain, ¹⁵Center for Genomics and Oncological Research (GENYO), Granada, Spain
Background/Purpose: Primary antiphospholipid syndrome (PAPS) is a rare autoimmune disease characterized by the presence of antiphospholipid antibodies and the occurrence of thrombotic events and pregnancy…
Abstract Number: 0103 • ACR Convergence 2023
Criteria and Non-criteria Antiphospholipid Autoantibodies Screening in Women with Unexplained Fetal Death, Pre-eclampsia And/or Fetal Growth Restriction: A Cross-sectional Study
Tiphaine Goulenok¹, Clothilde Gros¹, Arthur Mageau², Tiphaine Barral¹, Pascale Roland Nicaise¹, Marie Helene Saint Frison¹, Margot Bucau¹, Valerie Vivier¹, Valentine Marie Ferre², Agnes Bourgeois Moine¹, Thomas Papo² and Karim Sacre², ¹Assistance Publique Hopitaux de Paris, Paris, France, ²Université Paris Cité, Paris, France
Background/Purpose: Antiphospholipid syndrome (APS) is a cause of pregnancy morbidity. Late pregnancy morbidity occurs in up to 25% of pregnant women with APS and may…
Abstract Number: 0912 • ACR Convergence 2023
Inadequate Screening for Antiphospholipid Syndrome with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus
tooba Munawar¹, Mahnoor Sherazi² and Andras Perl³, ¹Upstate University Hospital, Jamesville, NY, ²Upstate University Hospital, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: Antiphospholipid Syndrome (APS) is classified into primary and secondary; the latter being associated with connective tissue disease. Systemic lupus erythematosus (SLE) is the most…
Abstract Number: 0682 • ACR Convergence 2022
Analysis of Recurrent Thrombotic Events in a Large Single-center Primary Antiphospholipid Syndrome Cohort: Results from APS-Rio Cohort After over Than 600 Patients-year of Follow-up
Gustavo Balbi¹, Guilherme de Jesús² and Flavio Victor Signorelli², ¹Universidade de São Paulo, São Paulo, Brazil, ²Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil
Background/Purpose: To estimate the incidence rate of new thrombotic events in a large single-center prospective cohort of primary antiphospholipid syndrome (PAPS) patients after approximately 5.5…
Abstract Number: 1466 • ACR Convergence 2022
Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus: Comparison Between QRISK and aGAPSS Scores
Alice Barinotti¹, Massimo Radin¹, Irene Cecchi², Silvia Grazietta Foddai¹, Simone Baldovino¹, Elisa Menegatti¹, Daniela Rossi¹, Vittorio Modena¹, Dario Roccatello¹ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Cardiovascular diseases (CVDs) represent one of the most life-threatening conditions that can affect SLE patients. Assessing the potential CVD risk of these patients is…
Abstract Number: 0683 • ACR Convergence 2022
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases: Clinical and Serological Characteristics, Results from the APS ACTION Clinical Database and Repository
Irene Cecchi¹, Massimo Radin², Silvia Grazietta Foddai², Maria Laura Bertolaccini³, Danieli De Andrade⁴, Maria Tektonidou⁵, Vittorio Pengo⁶, Guillermo Ruiz-Irastorza⁷, H. Michael Belmont⁸, Maria Gerosa⁹, Paul Fortin¹⁰, Chary Lopez-Pedrera¹¹, Zhouli Zhang¹², Tatsuya Atsumi¹³, Guilherme de Jesus¹⁴, Hannah Cohen¹⁵, Nina Kello¹⁶, Ware Branch¹⁷, Denis Wahl¹⁸, Laura Andreoli¹⁹, Esther Rodriguez²⁰, Michelle Petri²¹, Megan R.W. Barber²², Ricard Cervera²³, Jason Knight²⁴, Bahar Artim-Esen²⁵, Rohan Willis²⁶, Guillermo Pons-Estel²⁷, Doruk Erkan²⁸ and Savino Sciascia¹, ¹University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³King's College London, London, United Kingdom, ⁴University of São Paulo, São Paulo, Brazil, ⁵University of Athens, Athens, Greece, ⁶University of Padova, Padova, Italy, ⁷University of the Basque Country, Barakaldo, Spain, ⁸New York University School of Medicine, New York, NY, ⁹University of Milan, Milano, Italy, ¹⁰CHU de Québec Université Laval, Québec, QC, Canada, ¹¹Hospital Universitario Reina Sofía, Cordoba, Spain, ¹²Beijing Medical University, Beijing, China, ¹³Hokkaido University, Sapporo, Japan, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁵University College London, London, United Kingdom, ¹⁶Northwell Health, New York, NY, ¹⁷University of Utah Health, Salt Lake City, ¹⁸Nancy University Hospital, Nancy, France, ¹⁹University of Brescia, Brescia, Italy, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Johns Hopkins University School of Medicine, Baltimore, MD, ²²University of Calgary, Calgary, AB, Canada, ²³University of Barcelona, Barcelona, Spain, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Istanbul University, Istanbul, Turkey, ²⁶University of Texas, Galveston, TX, ²⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, ²⁸Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: APS ACTION is an international Clinical Database and Repository of persistently antiphospholipid antibody (aPL)-positive subjects, collecting demographic, medical history, and aPL data.This study focused…
Abstract Number: 1677 • ACR Convergence 2022
Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
Brian J. Mog¹, Elana R. Shaw¹, Michael S. Hwang¹, Alexander H. Pearlman¹, Sarah R. DiNapoli¹, Suman Paul¹, Chetan Bettegowda¹, Nickolas Papadopoulos¹, Sandra B. Gabelli¹, Michelle Petri², Antony Rosen¹, Shibin Zhou¹, Kenneth W. Kinzler¹, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the treatment of cancer and can be curative. CD19-targeted CAR-T cells hold promise for the treatment…
Abstract Number: 0684 • ACR Convergence 2022
Single Antiphospholipid Antibody Positive Thrombotic APS Patients’ Clinical Characteristics: Retrospective Results from the APS ACTION Clinical Database and Repository (Registry)
Silvia Grazietta Foddai¹, Irene Cecchi², Massimo Radin¹, Danieli De Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Guillermo Ruiz-Irastorza⁶, H. Michael Belmont⁷, Maria Gerosa⁸, Paul Fortin⁹, Rosario Lopez-Pedrera¹⁰, Zhouli Zhang¹¹, Tatsuya Atsumi¹², Guilherme de Jesus¹³, Hannah Cohen¹⁴, Nina Kello¹⁵, Ware Branch¹⁶, Denis Wahl¹⁷, Laura Andreoli¹⁸, Esther Rodriguez¹⁹, Michelle Petri²⁰, Ann E. Clarke²¹, Ricard Cervera²², Jason Knight²³, Bahar Artim-Esen²⁴, Rohan Willis²⁵, Guillermo Pons-Estel²⁶, Doruk Erkan²⁷, Dario Roccatello¹ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy, ³University of São Paulo, São Paulo, Brazil, ⁴University of Athens, Athens, Greece, ⁵University of Padova, Padova, Italy, ⁶University of the Basque Country, Barakaldo, Spain, ⁷New York University School of Medicine, New York, NY, ⁸University of Milan, Milano, Italy, ⁹CHU de Québec Université Laval, Québec, QC, Canada, ¹⁰University of Cordoba, Cordoba, Spain, ¹¹Beijing Medical University, Beijing, China, ¹²Hokkaido University, Sapporo, Japan, ¹³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁴University College London, London, United Kingdom, ¹⁵Northwell Health, New York, NY, ¹⁶University of Utah Health, Salt Lake City, ¹⁷Nancy University Hospital, Nancy, France, ¹⁸University of Brescia, Brescia, Italy, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Johns Hopkins University School of Medicine, Baltimore, MD, ²¹University of Calgary, Calgary, AB, Canada, ²²University of Barcelona, Barcelona, Spain, ²³University of Michigan, Ann Arbor, MI, ²⁴Istanbul University, Istanbul, Turkey, ²⁵University of Texas, Galveston, TX, ²⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, ²⁷Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: The APS ACTION is a network collecting and analyzing data ofaPL positive patients recruited by international centers. Based on the assumption that triple aPL-positive…
Abstract Number: 1689 • ACR Convergence 2022
Oral Ginger Supplementation Counteracts NETosis in Autoimmune Mouse Models and in Healthy Humans
Ramadan Ali¹, Miela Zahavi², Christine Rysenga¹, Cyrus Sarosh³, Claire Hoy¹, Kristen Demoruelle⁴ and Jason S Knight⁵, ¹University of Michigan, Ann Arbor, MI, ²Universtiy of Michigan, Ann Arbor, MI, ³University of Michigan, Temperance, MI, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: It has previously been reported that 6-gingerol, the most abundant phytochemical in ginger root, inhibits neutrophil phosphodiesterase activity and thereby counteracts neutrophil hyperactivity in…
Abstract Number: 0685 • ACR Convergence 2022
The Association of Antiphospholipid Antibodies with Previous SARS-CoV-2 Infection Among Elective Knee Replacement Patients
Lisa Mandl, Medha Barbhaiya, Robyn Lipschultz, Benjamin Swett, Myriam Lin, Agnes Cororaton, Dongmei Sun, Kethy Jules-elysee, Doruk Erkan and Friedrich Boettner, Hospital for Special Surgery, New York, NY
Background/Purpose: Acute SARS-CoV-2 infection has been associated with antiphospholipid antibodies (aPL), though it is unclear if aPL contribute to the hypercoagulability seen with COVID19, or…

« Previous Page
1
…
4
5
6
7
8
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].